LNC
MRNA icon

Lincoln National Corp’s Moderna MRNA Stock Holding History

Lincoln National Corp’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,275
Closed -$242K – 741
2024
Q1 		$242K Sell
2,275
-237
-9% -$23.9K ﹤0.01% 1054
2023
Q4 		$250K Sell
2,512
-280
-10% -$23.6K ﹤0.01% 953
2023
Q3 		$288K Sell
2,792
-161
-5% -$18K 0.01% 804
2023
Q2 		$359K Buy
2,953
+1,432
+94% +$191K 0.01% 728
2023
Q1 		$234K Sell
1,521
-154
-9% -$25.4K ﹤0.01% 863
2022
Q4 		$301K Buy
+1,675
New +$274K 0.01% 712
2022
Q3 		– Sell
-1,818
Closed -$259K – 898
2022
Q2 		$259K Buy
1,818
+435
+31% +$62.2K 0.01% 711
2022
Q1 		$239K Sell
1,383
-801
-37% -$135K ﹤0.01% 793
2021
Q4 		$555K Sell
2,184
-1,032
-32% -$302K 0.01% 488
2021
Q3 		$1.24M Buy
3,216
+855
+36% +$315K 0.03% 284
2021
Q2 		$555K Buy
2,361
+1
+0% +$179 0.01% 456
2021
Q1 		$309K Sell
2,360
-532
-18% -$77.1K 0.01% 610
2020
Q4 		$302K Sell
2,892
-1,245
-30% -$126K 0.01% 575
2020
Q3 		$293K Buy
+4,137
New +$288K 0.01% 514

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lincoln National Corp's MRNA Position: Q2 2024 in Review

Lincoln National Corp sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,275 shares — an estimated $242K sold.

Lincoln National Corp first reported a position in MRNA in Q3 2020 and held it in 14 quarters. The position peaked at $1.24M in Q3 2021. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Lincoln National Corp reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 2,275 Moderna shares in Q2 2024, an estimated $242K.
  • Lincoln National Corp first reported a position in Moderna in Q3 2020 and held it in 14 quarters.
  • Lincoln National Corp's Moderna position peaked at $1.24M in Q3 2021.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.